I'm serving as a Full Professor in the Department of Bioengineering at Hanyang University, Korea. I'm also an Adjunct Professor of Pharmaceuticals and Pharmaceutical Chemistry at University of Utah in United States, an Affiliate Professor at Medical School, University of Washington in United States, and Guest Professor at Sichuan University in China. My research interests include cancer gene therapy, immunotherapy, angiogenesis, combination of viral vectors and non-viral vectors, nanomedicine, and tumor biology. I have published 225 articles in leading academic journals such as Nature Medicine, JNCI, JCI, Cancer Research, Clinical Cancer Research, Molecular Therapy, Biomaterials, Human Gene Therapy, and JBC and has registered over 118 patents. In addition, oncolytic adenovirus (GM101) developed by myself was evaluated in phase I clinical trial for recurrent cancers, which yielded promising results. Recently, I have been focusing on translating my cutting-edge oncolytic adenovirus pipelines into clinic through establishment of GeneMedicine and active collaboration with global partners. GeneMedicine has built four pipelines based on oncolytic adenovirus against solid tumors (GM101, GM104), pancreatic cancers (GM102), and metastatic lung and liver cancers (GM103). I'm currently serving as a chief/deputy editor or editorial member in well-recognized international journals, such as Molecular Therapy, BMC Cancer, Cancer Gene Therapy, Oncolytic virotherapy, Advanced Drug Delivery Review, Regenerative Therapy, and Biomaterials. I was awarded the Excellence in Research Award from American Society of Gene Therapy in 2002 and Excellent Professor in Research Achievement from Yonsei University in 2003, 2005, 2007, 2008, and 2011. I also was awarded the Excellence in Research Award from Korean Society of Gene Therapy (2011, 2012, and 2014), Korean Government Ministry award from Ministry of Science (2013), LG Yonam Foundation (2016), International Society of Cancer Gene Therapy (2016), and Asia Pacific Consortium of Gene and Cell Therapy (2019). Recently, I received the BioTOP5 awards (bio-convergence part) from Biological Research Information Center (2019) and the commendation from the Korea Minister of Health and Welfare (2020) As a testament to my boundless pursuit for excellence and scientific advancements, I'm a current member of the National Academy of Engineering of Korea. Many of my students from I have gone on to impactful academic and industry careers.